Katie Kitrinos

Katie Kitrinos has extensive experience in the biopharmaceutical industry, with a strong background in virology. Katie currently holds the position of Senior Vice President, Preclinical Research and Development at Assembly Biosciences, Inc., a role they have held since March 2023. Prior to this, they were Vice President, Clinical Virology at the same company, starting in November 2020.

Before joining Assembly Biosciences, Katie worked at ViiV Healthcare as a Director from April 2018 to November 2020. In this role, they were responsible for various aspects of the company's operations.

Katie also spent a significant portion of their career at Gilead Sciences, where they held multiple positions. From October 2016 to March 2018, they served as a Director and led the HBV and HIV cure biomarker efforts. Prior to that, they were a Senior Research Scientist II from December 2007 to October 2016, leading the HBV clinical virology group.

Their earlier experience includes working at GlaxoSmithKline as an Investigator in the Biology, Clinical Virology Department from April 2003 to December 2007. Katie played a key role in introducing full-length HIV-1 envelope experience to the team and contributed to Phase II clinical trials.

Throughout their career, Katie Kitrinos has demonstrated expertise in virology, clinical trials, biomarker strategies, and leading cross-functional teams.

Katie Kitrinos pursued their education in a chronological manner. Katie first attended James Madison University from 1992 to 1996, where they obtained their Bachelor of Science degree in Biology. Subsequently, they enrolled at the University of North Carolina at Chapel Hill School of Medicine from 1996 to 2003, and successfully completed their PhD in Genetics and Molecular Biology.